CA2322327C - Treatment of viral disease in swine - Google Patents
Treatment of viral disease in swine Download PDFInfo
- Publication number
- CA2322327C CA2322327C CA002322327A CA2322327A CA2322327C CA 2322327 C CA2322327 C CA 2322327C CA 002322327 A CA002322327 A CA 002322327A CA 2322327 A CA2322327 A CA 2322327A CA 2322327 C CA2322327 C CA 2322327C
- Authority
- CA
- Canada
- Prior art keywords
- virus
- swine
- tilmicosin
- inf
- sirsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 30
- 238000011282 treatment Methods 0.000 title abstract description 8
- 201000010099 disease Diseases 0.000 title description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 3
- 230000003612 virological effect Effects 0.000 title description 3
- 229960000223 tilmicosin Drugs 0.000 claims abstract description 28
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 241000700605 Viruses Species 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 241000710788 Lelystad virus Species 0.000 claims description 9
- 206010000210 abortion Diseases 0.000 claims description 9
- 231100000176 abortion Toxicity 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- NESIVXZOSKKUDP-ARVJLQODSA-N (4r,5s,6s,7r,9r,11e,13e,15r,16r)-6-[(2r,3r,4s,5s,6r)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-7-[2-[(3s,5r)-3,5-dimethylpiperidin-1-yl]ethyl]-16-ethyl-4-hydroxy-15-[[(2r,3r,4r,5r,6r)-5-hydroxy-3,4-dimethoxy-6-methyloxan-2-yl]oxymethyl]-5,9,13 Chemical compound OP(O)(O)=O.O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O NESIVXZOSKKUDP-ARVJLQODSA-N 0.000 claims description 5
- 229960000757 tilmicosin phosphate Drugs 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 abstract description 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000282887 Suidae Species 0.000 description 25
- -1 cyano, ethylenedioxy, benzyl Chemical group 0.000 description 9
- 230000000694 effects Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000001475 halogen functional group Chemical group 0.000 description 4
- 244000144980 herd Species 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 208000021017 Weight Gain Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000001132 alveolar macrophage Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 230000005727 virus proliferation Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000032369 Primary transmission Diseases 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Fodder In General (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7646698P | 1998-03-02 | 1998-03-02 | |
| US60/076,466 | 1998-03-02 | ||
| PCT/US1999/004621 WO1999044619A1 (en) | 1998-03-02 | 1999-03-02 | Treatment of viral disease in swine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2322327A1 CA2322327A1 (en) | 1999-09-10 |
| CA2322327C true CA2322327C (en) | 2009-12-22 |
Family
ID=22132217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002322327A Expired - Fee Related CA2322327C (en) | 1998-03-02 | 1999-03-02 | Treatment of viral disease in swine |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6034070A (enExample) |
| EP (1) | EP0948967B1 (enExample) |
| JP (1) | JP4555472B2 (enExample) |
| AT (1) | ATE281173T1 (enExample) |
| AU (1) | AU2979899A (enExample) |
| CA (1) | CA2322327C (enExample) |
| CO (1) | CO5080775A1 (enExample) |
| DE (1) | DE69921530T2 (enExample) |
| DK (1) | DK0948967T3 (enExample) |
| ES (1) | ES2230802T3 (enExample) |
| MY (1) | MY124071A (enExample) |
| PT (1) | PT948967E (enExample) |
| SI (1) | SI0948967T1 (enExample) |
| TW (1) | TW565452B (enExample) |
| WO (1) | WO1999044619A1 (enExample) |
| ZA (1) | ZA991641B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506885B1 (en) * | 2001-09-27 | 2003-01-14 | The United States Of America As Represented By The Secretary Of Agriculture | Monoclonal antibodies to the drug tilmicosin and a method for detecting the same |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| CN1607937A (zh) * | 2001-10-19 | 2005-04-20 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
| ATE452896T1 (de) | 2002-03-12 | 2010-01-15 | Bristol Myers Squibb Co | C3-cyanoepothilonderivate |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2008012343A2 (en) | 2006-07-28 | 2008-01-31 | Intervet International B.V. | Macrolide synthesis process |
| CN103288904B (zh) * | 2013-06-28 | 2015-07-15 | 宁夏泰瑞制药股份有限公司 | 一种磷酸替米考星晶体的制备方法 |
| CN103483406A (zh) * | 2013-09-25 | 2014-01-01 | 宁夏泰瑞制药股份有限公司 | 一种磷酸替米考星的制备方法 |
| CN103923141B (zh) * | 2014-04-21 | 2016-04-27 | 西南大学 | 一种依托替米考星的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL69666A (en) * | 1982-09-13 | 1987-10-20 | Lilly Co Eli | 20-amino-20-deoxo-5-o-mycaminosyl-23-o-mycinosyltylonolide derivatives,their preparation and veterinary antibiotic use |
| US4820695A (en) * | 1982-09-13 | 1989-04-11 | Eli Lilly And Company | C-20-dihydro-deoxy-(cyclic amino)-derivatives of macrolide antibiotics |
| US5574020A (en) * | 1989-09-28 | 1996-11-12 | Eli Lilly And Company | Tilmicosin formulation |
| US5695766A (en) * | 1992-10-30 | 1997-12-09 | Iowa State University Research Foundation | Highly virulent porcine reproductive and respiratory syndrome viruses which produce lesions in pigs and vaccines that protect pigs against said syndrome |
| DK53595A (da) * | 1994-05-13 | 1995-11-14 | Iberica Cyanamid | Rekombinante PRRSV-proteiner, diagnostiske kits og vaccine indeholdende sådanne rekombinante PRRSV-proteiner |
| PT732340E (pt) * | 1995-03-14 | 2004-09-30 | Akzo Nobel Nv | Expressao de polipeptidos do virus da sindrome reprodutiva e respiratoria porcina na mesma celula |
-
1999
- 1999-03-01 DK DK99301503T patent/DK0948967T3/da active
- 1999-03-01 US US09/259,780 patent/US6034070A/en not_active Expired - Lifetime
- 1999-03-01 AT AT99301503T patent/ATE281173T1/de active
- 1999-03-01 ZA ZA9901641A patent/ZA991641B/xx unknown
- 1999-03-01 EP EP99301503A patent/EP0948967B1/en not_active Expired - Lifetime
- 1999-03-01 TW TW088103069A patent/TW565452B/zh not_active IP Right Cessation
- 1999-03-01 SI SI9930730T patent/SI0948967T1/xx unknown
- 1999-03-01 CO CO99012471A patent/CO5080775A1/es unknown
- 1999-03-01 DE DE69921530T patent/DE69921530T2/de not_active Expired - Lifetime
- 1999-03-01 ES ES99301503T patent/ES2230802T3/es not_active Expired - Lifetime
- 1999-03-01 PT PT99301503T patent/PT948967E/pt unknown
- 1999-03-01 MY MYPI99000736A patent/MY124071A/en unknown
- 1999-03-02 AU AU29798/99A patent/AU2979899A/en not_active Abandoned
- 1999-03-02 JP JP2000534220A patent/JP4555472B2/ja not_active Expired - Fee Related
- 1999-03-02 CA CA002322327A patent/CA2322327C/en not_active Expired - Fee Related
- 1999-03-02 WO PCT/US1999/004621 patent/WO1999044619A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP0948967B1 (en) | 2004-11-03 |
| ZA991641B (en) | 2000-09-01 |
| EP0948967A2 (en) | 1999-10-13 |
| JP2002505294A (ja) | 2002-02-19 |
| ATE281173T1 (de) | 2004-11-15 |
| EP0948967A3 (en) | 1999-10-20 |
| CO5080775A1 (es) | 2001-09-25 |
| US6034070A (en) | 2000-03-07 |
| TW565452B (en) | 2003-12-11 |
| DE69921530T2 (de) | 2005-10-27 |
| WO1999044619A1 (en) | 1999-09-10 |
| JP4555472B2 (ja) | 2010-09-29 |
| AU2979899A (en) | 1999-09-20 |
| CA2322327A1 (en) | 1999-09-10 |
| MY124071A (en) | 2006-06-30 |
| ES2230802T3 (es) | 2005-05-01 |
| SI0948967T1 (en) | 2005-06-30 |
| DK0948967T3 (da) | 2005-02-14 |
| DE69921530D1 (de) | 2004-12-09 |
| PT948967E (pt) | 2005-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2322327C (en) | Treatment of viral disease in swine | |
| CN110354139B (zh) | 一种抗猪流行性腹泻病毒感染的组合物及其应用 | |
| JP2021066728A (ja) | 偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤の調製におけるｅｇｃｇの応用、偽狂犬病ウイルス（ｐｒｖ）感染の予防及び／または治療製剤 | |
| CN113633649B (zh) | 瑞德西韦及其核苷的组合制剂在抗猪流行性腹泻病毒中的应用 | |
| KR101929141B1 (ko) | 돼지 사료에서의 나라신의 항바이러스 효과 | |
| US20150250743A1 (en) | Method of increasing or maintaining the reproductive performance of sows | |
| HU230325B1 (hu) | A valnemulin alkalmazása növekvő állománysűrűség okozta állatbetegségek kezelésére alkalmas gyógyszerkészítmények előállítására | |
| Higgins et al. | The epidemiology and control of an outbreak of camel pox in Bahrain | |
| Lubicz-Nawrocki et al. | Effect of α-chlorohydrin on the fertilizing ability of hamster epididymal spermatozoa | |
| Rae et al. | Reproductive performance of beef heifers: Effects of vulvo-vaginitis, Ureaplasmadiversum and prebreeding antibiotic administration | |
| AU2023370868A1 (en) | Use of gnrh antagonist in regulation and control of estrus of mammal | |
| Harper et al. | Spermicidal effect of antagonists of platelet-activating factor | |
| CN116687947B (zh) | 柴胡皂苷d在制备抗猪伪狂犬病毒药物中的用途 | |
| Kuroiwa et al. | Estrus synchronization and conception rate after a progesterone releasing intravaginal device (PRID) treatment from the early luteal phase in heifers | |
| Bhavna et al. | Evaluation and modulation of postpartum uterine health using proteolytic enzymes in crossbred dairy cows. | |
| US12343321B1 (en) | Method for ameliorating or avoiding the adverse effects of exogenous gonadotropins on reproductive performance | |
| ZA200208770B (en) | Praziquantel compounds for treating diseases due to sarcocystis, neospora, toxoplasma and isospora. | |
| WO2026001078A1 (zh) | 针对蓝耳病毒的新型药物 | |
| US3336190A (en) | Method of protecting the offspring of a herd of breeding swine from turbinate atrophy | |
| Zerobin et al. | A new progestin (Sa 45.249) for cycle control in pigs communication III: Confirmation of effectiveness in field trials | |
| Nath et al. | Reproductive performances of Crestar and PMSG administered to postpartum anoestrus cows | |
| Khanthusaeng et al. | Effect of short-term and long-term synthetic progesterone on estrous synchronization and conception rate in Thai-native goat | |
| CN121102257A (zh) | 安石榴苷在制备猪囊膜病毒感染防治组合物中的应用、猪囊膜病毒感染防治组合物及使用方法 | |
| JP2004502738A (ja) | 改良された受胎管理方法および関連組成物 | |
| SU1586649A1 (ru) | Способ регул ции репродуктивных функций сельскохоз йственных животных |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170302 |